scholarly journals Fracture risk with intermittent high-dose oral glucocorticoid therapy

2006 ◽  
Vol 56 (1) ◽  
pp. 208-214 ◽  
Author(s):  
Frank De Vries ◽  
Madelon Bracke ◽  
Hubert G. M. Leufkens ◽  
Jan-Willem J. Lammers ◽  
Cyrus Cooper ◽  
...  
Keyword(s):  
Fracture Risk ◽  
Glucocorticoid Therapy ◽  
High Dose ◽  
Oral Glucocorticoid ◽  
Dose Oral

scholarly journals Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study

2018 ◽  
Vol 13 (1) ◽  
Author(s):  
M. Amine Amiche ◽  
Shahab Abtahi ◽  
Johanna H. M. Driessen ◽  
Peter Vestergaard ◽  
Frank de Vries ◽  
...  
Keyword(s):  
Fracture Risk ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Cumulative Exposure ◽  
High Dose ◽  
Dose Oral ◽  
Oral Glucocorticoids ◽  
Control Study

High-dose glucocorticoid therapy impairs long-term memory, but not executive function

2005 ◽  
Vol 113 (08) ◽  
Author(s):  
R Brunner ◽  
D Schaefer ◽  
K Hess ◽  
P Parzer ◽  
F Resch ◽  
...  
Keyword(s):  
Executive Function ◽  
Glucocorticoid Therapy ◽  
Long Term Memory ◽  
High Dose ◽  
Term Memory

High‐dose glucocorticoid therapy is associated with shortening of activated partial thromboplastin time and prothrombin time

2021 ◽  
Author(s):  
Simone Canovi ◽  
Annalisa Pilia ◽  
Efrem Bonelli ◽  
Antonio Bonanno ◽  
Piera Zaldini ◽  
...  
Keyword(s):  
Prothrombin Time ◽  
Partial Thromboplastin Time ◽  
Activated Partial Thromboplastin Time ◽  
Glucocorticoid Therapy ◽  
High Dose

Novel perspectives of super-high dose sulfonylurea and high-dose oral prednisolone in an infant with DEND syndrome due to V64M heterozygote KCNJ11 mutation

2021 ◽  
Author(s):  
Galia Barash ◽  
Haim Bassan ◽  
Ayelet Livne ◽  
Lilach Benyamini ◽  
Eli Heyman ◽  
...  
Keyword(s):  
Oral Prednisolone ◽  
High Dose ◽  
Dose Oral

scholarly journals High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly HIV-positive Ugandan adults: a phase II open-label randomised controlled trial

2021 ◽  
Author(s):  
Fiona V Cresswell ◽  
David B Meya ◽  
Enock Kagimu ◽  
Daniel Grint ◽  
Lindsey te Brake ◽  
...  
Keyword(s):  
Adverse Events ◽  
Phase Ii ◽  
Tuberculous Meningitis ◽  
Geometric Mean ◽  
Standard Of Care ◽  
Hiv Positive ◽  
High Dose ◽  
Open Label ◽  
Dose Oral ◽  
Csf Levels

Abstract Background High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM). Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in HIV co-infection, and no cerebrospinal fluid (CSF) PK data exist from Africa. We hypothesized that high-dose rifampicin would increase serum and CSF concentrations without excess toxicity. Methods In this phase II open-label trial, Ugandan adults with suspected TBM were randomised to standard-of-care control (PO-10, rifampicin 10mg/kg/day), intravenous rifampicin (IV-20, 20mg/kg/day), or high-dose oral rifampicin (PO-35, 35mg/kg/day). We performed PK sampling on day 2 and 14. The primary outcomes were total exposure (AUC0-24), maximum concentration (Cmax), CSF concentration and grade 3-5 adverse events. Results We enrolled 61 adults, 92% were HIV-positive, median CD4 count was 50cells/µL (IQR 46–56). On day 2, geometric mean plasma AUC0-24hr was 42.9h.mg/L with standard-of-care 10mg/kg dosing, 249h.mg/L for IV-20 and 327h.mg/L for PO-35 (P<0.001). In CSF, standard-of-care achieved undetectable rifampicin concentration in 56% of participants and geometric mean AUC0-24hr 0.27mg/L, compared with 1.74mg/L (95%CI 1.2–2.5) for IV-20 and 2.17mg/L (1.6–2.9) for PO-35 regimens (p<0.001). Achieving CSF concentrations above rifampicin minimal inhibitory concentration (MIC) occurred in 11% (2/18) of standard-of-care, 93% (14/15) of IV-20, and 95% (18/19) of PO-35 participants. Higher serum and CSF levels were sustained at day 14. Adverse events did not differ by dose (p=0.34) Conclusion Current international guidelines result in sub-therapeutic CSF rifampicin concentration for 89% of Ugandan TBM patients. High-dose intravenous and oral rifampicin were safe, and respectively resulted in exposures ~6- and ~8-fold higher than standard-of-care, and CSF levels above the MIC

scholarly journals A Durable Response to Relapsing Clostridium difficile Colitis May Require Combined Therapy with High-dose Oral Vancomycin and Intravenous Immune Globulin

2006 ◽  
Vol 14 (4) ◽  
pp. 217-220 ◽  
Author(s):  
Lawrence A. Cone ◽  
Carlos Lopez ◽  
Harold L. Tarleton ◽  
V. Douglas Jodoin ◽  
Murray Taylor ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Immune Globulin ◽  
Combined Therapy ◽  
Intravenous Immune Globulin ◽  
High Dose ◽  
Oral Vancomycin ◽  
Durable Response ◽  
Dose Oral ◽  
Clostridium Difficile Colitis

Usefulness of High-Dose Oral Flecainide for Termination of Recent-Onset Atrial Fibrillation in Children

2018 ◽  
Vol 121 (12) ◽  
pp. 1530-1533
Author(s):  
Leonardo Liberman ◽  
Thomas J. Starc ◽  
Eric S. Silver
Keyword(s):  
Atrial Fibrillation ◽  
High Dose ◽  
Recent Onset ◽  
Dose Oral ◽  
Onset Atrial Fibrillation

High-Dose Oral and Intravenous Metoclopramide in Doxorubicin/Cyclophosphamide-Induced Emesis A Randomized Double-Blind Study

1987 ◽  
Vol 10 (3) ◽  
pp. 257-263 ◽  
Author(s):  
Stephen B. Edge ◽  
William K. Funkhouser ◽  
Arlene Berman ◽  
Claudia Seipp ◽  
Anne Tanner ◽  
...  
Keyword(s):  
Blind Study ◽  
High Dose ◽  
Double Blind Study ◽  
Double Blind ◽  
Dose Oral

Sudden onset blindness treated with pulse steroid therapy in a patient with microscopic polyangiitis

Open Medicine ◽  
2011 ◽  
Vol 6 (5) ◽  
pp. 631-633
Author(s):  
Yoshiro Horai ◽  
Tomoya Miyamura ◽  
Karin Shimada ◽  
Soichiro Takahama ◽  
Rumi Minami ◽  
...  
Keyword(s):  
Steroid Therapy ◽  
Microscopic Polyangiitis ◽  
Oral Prednisolone ◽  
Sudden Onset ◽  
High Dose ◽  
Pulse Steroid Therapy ◽  
Ocular Manifestations ◽  
Dose Oral ◽  
The Right ◽  
Pulse Steroid

AbstractWe report a 71-year-old male with microscopic polyangiitis (MPA) who developed sudden-onset, progressive, bilateral visual loss associated with a relapse of MPA symptoms. The patient was referred to our hospital, and treated with intravenous pulse steroid therapy and high-dose oral prednisolone. Although the right eye remained vision deficient, visual acuity in the left eye recovered. Ocular manifestations of MPA are quite uncommon. This case emphasizes the necessity of early detection and initiation of prompt therapy where ocular manifestations of MPA occur.

Sign in / Sign up

Export Citation Format

Share Document